NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $19.2857.

A number of equities research analysts have recently commented on NPCE shares. Cantor Fitzgerald reissued an “overweight” rating on shares of NeuroPace in a research note on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, June 24th. Mizuho began coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of NeuroPace in a research report on Wednesday, July 29th. Finally, Guggenheim restated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th.

Institutional Trading of NeuroPace

A number of large investors have recently made changes to their positions in NPCE. GSA Capital Partners LLP purchased a new stake in shares of NeuroPace during the 2nd quarter valued at about $1,836,000. Deutsche Bank AG purchased a new position in shares of NeuroPace in the second quarter worth approximately $14,919,000. First Light Asset Management LLC grew its position in NeuroPace by 82.3% during the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after buying an additional 1,110,484 shares during the period. Sei Investments Co. grew its position in NeuroPace by 51.4% during the first quarter. Sei Investments Co. now owns 121,476 shares of the company’s stock valued at $1,597,000 after buying an additional 41,233 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in NeuroPace during the second quarter valued at approximately $157,000. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Stock Up 2.0%

Shares of NeuroPace stock opened at $14.41 on Friday. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The company’s fifty day simple moving average is $15.23 and its two-hundred day simple moving average is $15.27. The company has a market cap of $494.55 million, a P/E ratio of -25.28 and a beta of 1.92. NeuroPace has a 12-month low of $8.88 and a 12-month high of $19.60.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $22.83 million during the quarter, compared to analysts’ expectations of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. Research analysts anticipate that NeuroPace will post -0.67 EPS for the current year.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.